logo
Types of Schizophrenia

Types of Schizophrenia

Health Line07-06-2025
Key takeaways
The DSM-5 no longer recognizes schizophrenia subtypes as separate diagnostic categories. However, the five classical subtypes (paranoid, hebephrenic, undifferentiated, residual, and catatonic) can still be helpful as specifiers for treatment planning.
Schizophrenia affects approximately 1% of people in the United States, with men typically receiving a diagnosis in their late teens to early 20s and women typically receiving a diagnosis in their late 20s to early 30s.
When schizophrenia occurs in children (which is rare), symptoms in older children and teens can include social withdrawal, sleep disruptions, impaired school performance, irritability, irregular behavior, and substance use.
Schizophrenia is a chronic mental health disorder that affects:
emotions
the ability to think rationally and clearly
the ability to interact with and relate to others
The National Alliance on Mental Illness (NAMI) reports that research indicates that schizophrenia affects close to 1% of people in the United States. Men typically receive a schizophrenia diagnosis in their late teens to early 20s. Women typically receive a diagnosis in their late 20s to early 30s.
Episodes of the illness can come and go, similar to the process of remission. When there's an 'active' period, an individual might experience:
Current DSM-5 status
Diagnostic changes were made for several disorders in the new Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, text revision (DSM-5-TR), including schizophrenia. In the past, an individual only had to have one of the symptoms to receive a confirmed diagnosis Now, a person must have at least two of the symptoms.
The DSM-5 also removed the subtypes as separate diagnostic categories, based on the presenting symptom. This was found to not be helpful, since many subtypes overlapped with one another and were thought to decrease the diagnostic validity, according to the American Psychiatric Association (APA).
Instead, these subtypes are now specifiers for the overarching diagnosis, to provide more detail for the clinician.
Subtypes of schizophrenia
Although the subtypes don't exist as separate clinical disorders anymore, they can still be helpful as specifiers and for treatment planning. There are five classical subtypes:
paranoid
hebephrenic
undifferentiated
residual
catatonic
Paranoid schizophrenia
In 2013, the APA determined that paranoia was a positive symptom of the disorder. Paranoid schizophrenia was no longer considered a separate condition.
However, the subtype description is still used because of how common this symptom is. Symptoms include:
delusions
hallucinations
disorganized speech (word salad, echolalia)
trouble concentrating
behavioral impairment (impulse control challenges, emotional lability)
flat affect
Hebephrenic (disorganized) schizophrenia
Hebephrenic or disorganized schizophrenia is still recognized by the International Statistical Classification of Diseases and Related Health Problems (ICD-10), although it's been removed from the DSM-5-TR.
In this variation of schizophrenia, the individual does not have hallucinations or delusions. Instead, they experience disorganized behavior and speech. This can include:
flat affect (inability to display emotions)
speech disturbances
disorganized thinking
involuntary or unexpected emotions or facial reactions
trouble with daily activities
Undifferentiated schizophrenia
Undifferentiated schizophrenia was the term used to describe when an individual displayed behaviors that were applicable to more than one type of schizophrenia. For instance, an individual who had catatonic behavior but also had delusions or hallucinations and disorganized speech might have received a diagnosis of undifferentiated schizophrenia.
With the new diagnostic criteria, this merely signifies to the clinician that a variety of symptoms are present.
Residual schizophrenia
This 'subtype' is a bit tricky. It's been used when a person has a previous diagnosis of schizophrenia but no longer has any prominent symptoms of the disorder. The symptoms have generally lessened in intensity.
Residual schizophrenia usually includes more 'negative' than positive symptoms, such as:
flattened affect
psychomotor difficulties
slowed speech
limited attentiveness to personal hygiene
Many people with schizophrenia go through periods where their symptoms wax and wane (increase and decrease) and vary in frequency and intensity. Therefore, this designation is rarely used anymore.
Catatonic schizophrenia
Although catatonic schizophrenia had been listed as a subtype in the first Diagnostic and Statistical Manual of Mental Disorders first edition (1952) through the DSM-4 (1994), the DSM-5 removed it as a subtype. Catatonia is now considered a specifier. This is because it occurs in a variety of psychiatric and general medical conditions.
Catatonic schizophrenia typically presents itself as immobility, but it can also look like:
mimicking behavior
mutism (inability to speak)
a stupor-like condition (reduced responsiveness)
Childhood schizophrenia
Childhood schizophrenia isn't a subtype but rather an indicator of the time of diagnosis. A diagnosis in children is fairly uncommon.
When it does occur, it can be severe. Early onset schizophrenia typically occurs between ages 13 and 18 years. A diagnosis under age 13 years is considered very early onset and is extremely rare.
Symptoms in very young children are similar to those of developmental disorders, such as autism and attention deficit hyperactivity disorder (ADHD). These symptoms can include:
language delays
late or unusual crawling or walking
irregular motor movements
It's important to rule out developmental issues when considering a very early onset schizophrenia diagnosis.
Symptoms in older children and teens include:
social withdrawal
sleep disruptions
impaired school performance
irritability
irregular behavior
substance use
Younger individuals are less likely to have delusions, but they're more likely to have hallucinations. As teens get older, more typical symptoms of schizophrenia — like those seen in adults — usually emerge.
It's important to have a knowledgeable professional make a diagnosis of childhood schizophrenia because it's so rare. It's crucial to rule out any other condition, including substance use or an organic medical issue.
A child psychiatrist with experience in childhood schizophrenia should lead the treatment team and discussions about its plan. Treatment typically involves a combination approach that can include:
Conditions related to schizophrenia
Schizoaffective disorder
Schizoaffective disorder is a separate and different condition from schizophrenia, but sometimes it gets lumped in with it. This disorder has elements of both schizophrenia and mood disorders.
Psychosis, which involves a loss of connection with reality, is often a component. Mood disorders can include either mania or depression.
Schizoaffective disorder is further classified into subtypes based on whether a person has only depressive episodes or whether they also have manic episodes with or without depression. Symptoms can include:
paranoid thoughts
delusions or hallucinations
trouble concentrating
depression
hyperactivity or mania
limited attentiveness to personal hygiene
appetite disturbance
sleep disruptions
social withdrawal
disorganized thinking or behavior
Diagnosis is typically made through a thorough physical exam, interview, and psychiatric evaluation. It's important to rule out any medical conditions or any other mental illnesses like bipolar disorder. Treatments include:
medications
group or individual therapy
practical life skills training
Other related conditions
Other related conditions to schizophrenia include:
delusional disorder
brief psychotic disorder
schizophreniform disorder
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?

Yahoo

time38 minutes ago

  • Yahoo

Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering CVS Health (CVS), which belongs to the Zacks Medical Services industry. When looking at the last two reports, this drugstore chain and pharmacy benefits manager has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 32.64%, on average, in the last two quarters. For the last reported quarter, CVS Health came out with earnings of $2.25 per share versus the Zacks Consensus Estimate of $1.71 per share, representing a surprise of 31.58%. For the previous quarter, the company was expected to post earnings of $0.89 per share and it actually produced earnings of $1.19 per share, delivering a surprise of 33.71%. Thanks in part to this history, there has been a favorable change in earnings estimates for CVS Health lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. CVS Health has an Earnings ESP of +6.35% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #2 (Buy), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on July 31, 2025. With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss. Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

UnitedHealth Group (UNH) Stock Sinks As Market Gains: What You Should Know
UnitedHealth Group (UNH) Stock Sinks As Market Gains: What You Should Know

Yahoo

time39 minutes ago

  • Yahoo

UnitedHealth Group (UNH) Stock Sinks As Market Gains: What You Should Know

UnitedHealth Group (UNH) closed the most recent trading day at $307.56, moving -5.7% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.48% for the day. Elsewhere, the Dow lost 0.02%, while the tech-heavy Nasdaq added 0.94%. Shares of the largest U.S. health insurer witnessed a gain of 8.27% over the previous month, beating the performance of the Medical sector with its gain of 2.8%, and the S&P 500's gain of 5.13%. The investment community will be closely monitoring the performance of UnitedHealth Group in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2025. The company's earnings per share (EPS) are projected to be $5.08, reflecting a 25.29% decrease from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $111.85 billion, indicating a 13.14% upward movement from the same quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $22.07 per share and a revenue of $449.46 billion, signifying shifts of -20.21% and +12.29%, respectively, from the last year. Investors should also pay attention to any latest changes in analyst estimates for UnitedHealth Group. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.54% lower. As of now, UnitedHealth Group holds a Zacks Rank of #4 (Sell). From a valuation perspective, UnitedHealth Group is currently exchanging hands at a Forward P/E ratio of 14.78. This indicates a premium in contrast to its industry's Forward P/E of 13.39. One should further note that UNH currently holds a PEG ratio of 1.55. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - HMOs industry had an average PEG ratio of 1.01 as trading concluded yesterday. The Medical - HMOs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 34, finds itself in the top 14% echelons of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts
Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts

Yahoo

time39 minutes ago

  • Yahoo

Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts

Tenet Healthcare (THC) closed the most recent trading day at $172.22, moving -2.94% from the previous trading session. This change lagged the S&P 500's 0.48% gain on the day. On the other hand, the Dow registered a loss of 0.02%, and the technology-centric Nasdaq increased by 0.94%. Heading into today, shares of the hospital operator had gained 3.25% over the past month, outpacing the Medical sector's gain of 2.8% and lagging the S&P 500's gain of 5.13%. Market participants will be closely following the financial results of Tenet Healthcare in its upcoming release. The company plans to announce its earnings on July 22, 2025. The company is expected to report EPS of $2.84, up 22.94% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.15 billion, up 0.85% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $12.73 per share and revenue of $20.9 billion, indicating changes of +7.15% and +1.12%, respectively, compared to the previous year. Any recent changes to analyst estimates for Tenet Healthcare should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.33% higher. Tenet Healthcare is currently a Zacks Rank #3 (Hold). In the context of valuation, Tenet Healthcare is at present trading with a Forward P/E ratio of 13.94. Its industry sports an average Forward P/E of 11.83, so one might conclude that Tenet Healthcare is trading at a premium comparatively. We can additionally observe that THC currently boasts a PEG ratio of 1.29. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Hospital industry was having an average PEG ratio of 1.32. The Medical - Hospital industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store